Tricida files for $150M IPO

Renal disease company Tricida Inc. (South San Francisco, Calif.) filed to raise up to $150 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan and Cowen.

In 2H19, Tricida plans to submit an NDA to FDA seeking accelerated approval of TRC101, the company’s lead program to treat metabolic acidosis. In the completed Phase III TRCA-301 study, the compound met the primary endpoint of increasing blood bicarbonate from baseline to 12 weeks vs. placebo (59.2% with an increase of ≥4 mEq/L or a level in the normal range vs. 22.5% for placebo, p<0.0001)...